| Makar Eyecare Llc | |
|
341 W Tudor Rd, Suite 101, Anchorage, AK 99503-6639 | |
| (907) 770-6652 | |
| Not Available |
| Full Name | Makar Eyecare Llc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 341 W Tudor Rd, Anchorage, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497184840 | NPI | - | NPPES |
| 1607601 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 431213 (Alaska) | Primary |
| Provider Name | Anthony J Makar |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1619047248 PECOS PAC ID: 1951359165 Enrollment ID: I20050104001096 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
| Provider Name | Rebecca J Makar |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1760552384 PECOS PAC ID: 2860440070 Enrollment ID: I20050104001101 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
| Provider Name | Elizabeth J Bow |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1265662019 PECOS PAC ID: 2163576265 Enrollment ID: I20090824000230 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
| Provider Name | Alyxandria A.m. Danger |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1316222169 PECOS PAC ID: 9638345945 Enrollment ID: I20120106000672 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
| Provider Name | Eliza Salvo |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1437468774 PECOS PAC ID: 5597082610 Enrollment ID: I20150327002331 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
| Provider Name | Rowena A. R. Rivera-garcia |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1942670450 PECOS PAC ID: 7618286212 Enrollment ID: I20160527001903 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
| Provider Name | Herbert Tanner Wentzien |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1316431257 PECOS PAC ID: 2264789536 Enrollment ID: I20180717003720 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
| Provider Name | Adam Scott Clark |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1700431749 PECOS PAC ID: 0244560118 Enrollment ID: I20190919002878 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
| Provider Name | Bethany Lynn Becker |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1447804984 PECOS PAC ID: 2365773496 Enrollment ID: I20191003002759 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
| Provider Name | Scott James Habermann |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1518536184 PECOS PAC ID: 1850794058 Enrollment ID: I20210726002771 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Makar Eyecare Llc 341 W Tudor Rd, Suite 101, Anchorage, AK 99503-6639 Ph: (907) 770-6652 | Makar Eyecare Llc 341 W Tudor Rd, Suite 101, Anchorage, AK 99503-6639 Ph: (907) 770-6652 |
News Archive
Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).
Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.
Researchers developed this treatment for patients with mild-to-moderate obesity to reduce the attrition that is common with weight-loss efforts.
A new study that will look at 50,000 sisters of women diagnosed with breast cancer opened today for enrollment across the United States. The Sister Study, conducted by the National Institute of Environmental Health Sciences (NIEHS), will investigate environmental and genetic causes of breast cancer.
› Verified 6 days ago
Dr. Gary Michael Kjome, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1000 E Dimond Blvd Ste 101, Anchorage, AK 99515 Phone: 907-349-6932 Fax: 907-349-6347 | |
Marko J Hrgovic, OD Optometrist Medicare: Medicare Enrolled Practice Location: 4125 Debarr Rd, Anchorage, AK 99508 Phone: 907-269-9542 Fax: 907-269-9541 | |
Dr. Patrick Reber, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1345 W 9th Ave, Anchorage, AK 99501 Phone: 907-272-2557 Fax: 907-274-4932 | |
Makar Eyecare Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4411 Business Park Blvd, Bldg. M Ste 10, Anchorage, AK 99503 Phone: 907-770-6652 Fax: 907-770-3668 | |
North Star Optical, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5710 Denali St, Anchorage, AK 99518 Phone: 907-444-8854 Fax: 888-612-1315 | |
Victoria Ann Blower, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 207 E Northern Lights Blvd, Ste 101, Anchorage, AK 99503 Phone: 907-272-9800 Fax: 907-277-1398 | |
Dimond Vision Clinic Optometrist Medicare: Medicare Enrolled Practice Location: 1000 E Dimond Blvd Ste 101, Anchorage, AK 99515 Phone: 907-349-6932 Fax: 907-349-6347 |